EGFR and adenocarcinoma: The combination of simvastatin and gefitinib resulted in higher RR (40% vs. 0%, p = 0.043) and longer PFS (3.6 months vs. 1.7 months, p = 0.027) compared with gefitinib alone in subgroup of patients with wildtype EGFR non-adenocarcinomas. (NCT00452244) Han et al. (2011)